The global shingles vaccine market is estimated at US$6.27 billion in 2026 and is projected to reach US$27.9 billion by 2036, expanding at a 16.1% CAGR, according to Fact.MR analysis. The market is expected to create an absolute dollar opportunity of US$21.63 billion during the 2026–2036 period as adult immunization programs expand across major healthcare systems.

The growth outlook is closely tied to aging populations and wider adoption of adult vaccination programs. Recombinant zoster vaccines account for 54% of product share in 2026, while preventive immunization represents 58% of application value. Australia and Canada are projected to record CAGRs of 17.4% and 16.7%, respectively, through 2036.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=10175

Recombinant Vaccines Lead the Shingles Vaccine Market

Fact.MR is a market research and consulting company that provides industry analysis, market forecasts, and competitive intelligence across global markets.

The shingles vaccine market covers prophylactic vaccines designed to prevent herpes zoster reactivation among adult populations. Product categories include recombinant zoster vaccines, live attenuated zoster vaccines, mRNA-based vaccines, and protein subunit vaccines.

Recombinant zoster vaccines currently hold the largest product position. The segment represents approximately 54% of total market value in 2026. Strong clinical efficacy data, regulatory approvals across North America and Europe, and established procurement channels support this position.

Preventive immunization accounts for 58% of application value in 2026. Routine adult vaccination schedules, high-risk prevention protocols, and expanding national immunization programs are key demand channels.

The market stood at approximately US$5.4 billion in 2025. It is estimated to add US$21.63 billion between 2026 and 2036, according to the Fact.MR forecast.

mRNA Platforms Gain Attention as Vaccine Development Advances

mRNA-based shingles vaccines remain smaller than established recombinant products, but their development pipeline is expanding. Candidates based on lipid nanoparticle delivery, synthetic mRNA platforms, and self-amplifying RNA systems are being evaluated for targeted immune responses.

The development focus also includes improved thermostability and simpler dosing approaches. These characteristics could become relevant in markets where cold-chain infrastructure remains limited.

Fact.MR identifies mRNA platforms as an opportunity area as candidates progress through clinical trials. The report notes that production scalability and clinical data will influence their ability to compete with established recombinant vaccines.

High per-dose costs remain a constraint. Cold-chain infrastructure gaps can also restrict distribution in emerging markets, while limited awareness among adults and primary care providers can slow voluntary vaccination outside established programs.

Australia and Canada Show Strong Growth Outlook

Australia is projected to lead country-level growth at a 17.4% CAGR through 2036. Canada follows with a projected CAGR of 16.7%. France is expected to expand at 16.3%, while the United Kingdom is projected at 15.6%.

The United States is forecast to grow at 15.4% during the same period. Germany and Japan are projected to record CAGRs of 15.1% and 14.8%, respectively.

Australia's growth outlook reflects expanding domestic demand, industry investment, and favorable policy conditions. In Canada, growing demand and evolving infrastructure are identified as supporting factors.

North America presents varied market conditions. The United States remains a mature market, while Canada is projected to experience faster growth.

Europe continues to show steady demand, with Germany and the United Kingdom supported by established healthcare infrastructure and regulatory frameworks.

Government Programs Create New Procurement Channels

Expansion of national adult immunization programs is opening additional public procurement channels across Europe, Asia Pacific, and North America. Government tender pipelines in mid-income countries are another opportunity identified by Fact.MR.

Elderly care facilities in Asia Pacific and Latin America also represent underpenetrated institutional demand channels. Distribution expansion and direct-to-customer platforms are improving access across several markets.

Shambhu Nath Jha, Principal Consultant at Fact.MR, said, “The shingles vaccine market is entering a structural growth phase as national immunization programs expand adult vaccination coverage beyond high income markets. Recombinant platforms remain the primary revenue base, but mRNA candidates are advancing toward late stage trials, which could reshape the competitive and pricing landscape within the next five years.”

Jha added that reimbursement inclusion in public healthcare budgets across Europe and Asia Pacific could become a key market inflection point, particularly where coverage gaps remain wide despite aging population demographics.

Competitive Landscape

GlaxoSmithKline plc. (GSK), Pfizer Inc., Merck & Co. Inc., CanSinoBIO (CanSino Biologics Inc.), Vaccitech plc., GC Biopharma Corp., GeneOne Life Science Inc., SK bioscience Co. Ltd., AIM Vaccine Co. Ltd., and Dynavax Technologies Corporation are identified among the companies participating in the global shingles vaccine market.

Recent industry developments include expanded age-based indications for GSK's Shingrix in multiple Asia Pacific markets in 2025. Pfizer advanced an mRNA-based shingles vaccine candidate into Phase 2 clinical trials in 2025. In 2026, CanSinoBIO launched a recombinant shingles vaccine in select domestic and export markets.

The competitive environment remains moderately fragmented, with companies differentiated by product portfolios, geographic presence, technology capabilities, distribution networks, and customer relationships.

To View Related Report

https://social.mytamam.com/blogs/40318/Global-Cladding-Market-to-Reach-128-79-Billion-by-2036

https://net-pals.com/blogs/35608/Global-Cladding-Market-Set-to-Reach-128-79-Billion-by

https://acmingle.com/blogs/20437/Global-Cladding-Market-Projected-to-Reach-128-79-Billion-by

https://zeuspage.org/blogs/55895/Global-Cladding-Market-Expected-to-Hit-128-79-Billion-by

About Fact.MR

Fact.MR is a global market research and consulting firm providing market intelligence, forecasts, and strategic analysis across industries. Its research combines secondary research, primary interviews, demand-side modelling, company benchmarking, pricing analysis, and trade-flow validation.

For the shingles vaccine market study, Fact.MR's methodology incorporates 100+ secondary sources, 50+ company product portfolios, analysis across 30+ countries, and 20+ primary interviews with manufacturers, distributors, end users, and industry specialists.